Simulation and prediction of in vivo drug metabolism in human populations from in vitro data
about
Top-down, Bottom-up and Middle-out Strategies for Drug Cardiac Safety Assessment via Modeling and SimulationsRecent Advances in Development and Application of Physiologically-Based Pharmacokinetic (PBPK) Models: a Transition from Academic Curiosity to Regulatory AcceptanceNovel in vitro and mathematical models for the prediction of chemical toxicityPhysiologically Based Pharmacokinetic (PBPK) Modeling and Simulation Approaches: A Systematic Review of Published Models, Applications, and Model VerificationThe Simcyp population-based ADME simulatorA Three-Pulse Release Tablet for Amoxicillin: Preparation, Pharmacokinetic Study and Physiologically Based Pharmacokinetic ModelingScreening of Genetic Polymorphisms of CYP3A4 and CYP3A5 Genes.Utility of physiologically based absorption modeling in implementing Quality by Design in drug developmentCombining the 'bottom up' and 'top down' approaches in pharmacokinetic modelling: fitting PBPK models to observed clinical dataPhysiology-based IVIVE predictions of tramadol from in vitro metabolism data.First dose in neonates: are juvenile mice, adults and in vitro-in silico data predictive of neonatal pharmacokinetics of fluconazole.Using physiologically based models for clinical translation: predictive modelling, data interpretation or something in-between?Systems Toxicology: Real World Applications and Opportunities.Use of silkworms for identification of drug candidates having appropriate pharmacokinetics from plant sources.A systems biology approach to dynamic modeling and inter-subject variability of statin pharmacokinetics in human hepatocytes.Identification of In Vitro Metabolites of Amoxicillin in Human Liver Microsomes by LC-ESI/MS.The relative importance of CYP26A1 in hepatic clearance of all-trans retinoic acid.Alternative (non-animal) methods for cosmetics testing: current status and future prospects-2010.Assessment of algorithms for predicting drug-drug interactions via inhibition mechanisms: comparison of dynamic and static models.A physiologically based pharmacokinetic model of the minipig: data compilation and model implementation.A pilot randomized, placebo controlled, double blind phase I trial of the novel SIRT1 activator SRT2104 in elderly volunteers.Maraviroc: in vitro assessment of drug-drug interaction potentialPhysiologically based pharmacokinetic modeling and simulation in pediatric drug developmentVariability of voriconazole plasma concentrations after allogeneic hematopoietic stem cell transplantation: impact of cytochrome p450 polymorphisms and comedications on initial and subsequent trough levelsEffect of ketoconazole and diltiazem on the pharmacokinetics of apixaban, an oral direct factor Xa inhibitor.The application of global sensitivity analysis in the development of a physiologically based pharmacokinetic model for m-xylene and ethanol co-exposure in humans.An overview of the evidence and mechanisms of herb-drug interactions.Inter-individual variability in the pre-clinical drug cardiotoxic safety assessment--analysis of the age-cardiomyocytes electric capacitance dependence.Role of Recombinant DNA Technology to Improve LifeRole of DNA Methylation on the Expression of the Anthracycline Metabolizing Enzyme AKR7A2 in Human Heart.Content and activity of human liver microsomal protein and prediction of individual hepatic clearance in vivo.A pregnancy physiologically based pharmacokinetic (p-PBPK) model for disposition of drugs metabolized by CYP1A2, CYP2D6 and CYP3A4Interactions between CYP2E1 and CYP2B4: effects on affinity for NADPH-cytochrome P450 reductase and substrate metabolism.Effect of reducing the paediatric stavudine dose by half: a physiologically-based pharmacokinetic model.Addressing Early Life Sensitivity Using Physiologically Based Pharmacokinetic Modeling and In Vitro to In Vivo Extrapolation.Predicted metabolic drug clearance with increasing adult age.Bioanalysis in drug discovery and development.Dose selection based on physiologically based pharmacokinetic (PBPK) approaches.Cytochrome P450 reaction-phenotyping: an industrial perspective.Intestinal permeability and its relevance for absorption and elimination.
P2860
Q26739743-0B019525-2DA0-4433-9B90-38E140838310Q26745824-49D30EEF-B932-4924-8C4F-E81CEEF9FAC1Q26851492-B5D00F2B-2587-4AAB-AD37-5D68D087A5DDQ28088352-870051C9-FB94-4973-B24B-33ED5DFDE2CCQ28308225-67FE032D-5D2A-4EA0-9CA5-747E2A38897EQ28553344-48E05EB5-A6CD-4080-80A2-825D72AE499EQ30357429-A64FA735-0C6F-48BA-A5B3-E8296EDBDB00Q30498061-3466BFCC-93B2-4F55-B08B-7178A823490BQ30666721-B9591E5B-A42A-4606-B368-7D9EDF902537Q30837825-AFED8BCE-B519-479C-BDD1-E1B135E4EC8DQ30844731-556A7263-7ADE-4C50-9BDD-304579F32FBEQ31086222-504D2D99-25CC-4BFD-91A0-C5E0D5038D48Q33577370-1A490869-98E9-4E6C-8AC9-57D84D9C1E6BQ33600446-A775BF31-7CC7-4C23-99A3-1A20291566B1Q33891588-00E31932-A859-4931-9C1D-443622829410Q33953636-39277B06-0970-4FA7-92D0-E326332F86C6Q34005757-43F54787-2892-458A-BB3E-6D202152528FQ34181630-F9B3A7E7-DF25-4642-A445-E2D6174ADA76Q34476096-B611B156-B444-48BB-BF99-24F455EAC8DDQ34487999-80FDEA3A-A7A9-4E24-A40E-169D23C358ABQ34531843-DB5D1D3E-618F-44B7-994D-BEF6BD51A8D5Q34594626-A9911BBC-D79F-48E9-9FBF-B3E000DCB32CQ34658074-534AAAB8-41D1-4F26-A9DF-08D4C5CC339FQ35169112-C202A6A2-BB97-457B-BFB7-3026B11E3FBDQ35557449-E6CB8AED-4463-4736-A849-40D98BB632FDQ35796328-5D834BF6-EF8D-46E6-B940-7C56116385C5Q35919968-9131784F-8438-4208-B271-AA594059D3A9Q35951965-D974549E-199D-4133-AEF1-D7A97A2AFDA2Q36239956-F7BD3756-22B1-40AB-BCE0-5D0B033F0E21Q36276059-6901948E-3A8A-40DB-8965-72A3D88C96A5Q36346340-8081F9B3-A1BC-46BB-BEEA-22E22BC0A836Q36390289-B18036CB-ADFA-4385-8966-009D7346EEF3Q36497669-CA4EC14D-B6FA-449D-9FBC-6A024E1FC9DAQ36558893-8DA68F72-F06E-4698-BDDA-02F45DBA789CQ36657666-C285B551-7256-468B-9E49-31FCD9A186DFQ36729942-6CA3A4CC-D2B7-43B5-91B9-ADE6CDC99164Q36855961-50668EE8-8302-40B9-B3BE-7A7A329AC6C6Q36910606-E1648DE5-DC80-4B40-B17F-22C75C73BEC1Q36960539-2180EC9C-CA76-4CAE-8347-B8C03E8797C4Q36985043-50047FAF-6B18-4D5C-A1DA-937EEFFDF4F5
P2860
Simulation and prediction of in vivo drug metabolism in human populations from in vitro data
description
2007 nî lūn-bûn
@nan
2007 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Simulation and prediction of i ...... populations from in vitro data
@ast
Simulation and prediction of i ...... populations from in vitro data
@en
Simulation and prediction of i ...... populations from in vitro data
@nl
type
label
Simulation and prediction of i ...... populations from in vitro data
@ast
Simulation and prediction of i ...... populations from in vitro data
@en
Simulation and prediction of i ...... populations from in vitro data
@nl
prefLabel
Simulation and prediction of i ...... populations from in vitro data
@ast
Simulation and prediction of i ...... populations from in vitro data
@en
Simulation and prediction of i ...... populations from in vitro data
@nl
P2860
P3181
P356
P1476
Simulation and prediction of i ...... populations from in vitro data
@en
P2093
Amin Rostami-Hodjegan
Geoffrey T Tucker
P2860
P2888
P3181
P356
10.1038/NRD2173
P407
P577
2007-02-01T00:00:00Z